体内CRISPR/Cas9筛选鉴定Pbrm1为小鼠髓系白血病发展的调控因子
研究在小鼠造血干/祖细胞中同时功能失活Tet2和Tet3后移植建立髓系白血病模型,再进行表观遗传因子 pooled CRISPR/Cas9 编辑筛选,发现Pbrm1缺失可缩短白血病潜伏期、减弱干扰素信号和MHC II表达,PBRM1结合IRF1等基因启动子调控干扰素通路。
要点
- 在Tet2/Tet3双失活的鼠髓系白血病模型中,Pbrm1缺失促进白血病发生并显著缩短潜伏期。
- Pbrm1缺陷白血病细胞免疫原性降低,表现为干扰素信号减弱和MHC II表达减少。
- PBRM1结合IRF1等干扰素通路基因启动子,进而调控MHC II表达。
核心结论
- Pbrm1在白血病进展中具有新作用,其缺失促进小鼠髓系白血病发生。
- 转录调控干扰素信号可影响白血病细胞与免疫系统的相互作用。
研究设计与样本
- 研究为体内 pooled CRISPR/Cas9 基因编辑筛选,使用原代小鼠造血干/祖细胞(HSPCs)。
- 先在小鼠HSPCs中功能失活Tet2和Tet3后移植建立髓系白血病模型,再对表观遗传因子进行pooled CRISPR/Cas9编辑筛选。
主要发现
- 筛选鉴定Pbrm1/Baf180为疾病进展的负向驱动因子。
- Pbrm1缺失促进白血病发生,并显著缩短潜伏期。
- Pbrm1缺陷白血病细胞免疫原性较低,干扰素信号减弱,MHC II表达减少。
- PBRM1结合部分干扰素通路基因启动子,最显著为IRF1,IRF1进而调控MHC II表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CRISPR/Cas9 screening approaches are powerful tool for identifying in vivo cancer dependencies. Hematopoietic malignancies are genetically complex disorders in which the sequential acquisition of somatic mutations generates clonal diversity. Over time, additional cooperating mutations may drive disease progression. Using an in vivo pooled gene editing screen of epigenetic factors in primary murine hematopoietic stem and progenitor cells (HSPCs), we sought to uncover unrecognized genes that contribute to leukemia progression. We, first, modeled myeloid leukemia in mice by functionally abrogating both Tet2 and Tet3 in HSPCs, followed by transplantation. We, then, performed pooled CRISPR/Cas9 editing of genes encoding epigenetic factors and identified Pbrm1/Baf180, a subunit of the polybromo BRG1/BRM-associated factor SWItch/Sucrose Non-Fermenting chromatin-remodeling complex, as a negative driver of disease progression. We found that Pbrm1 loss promoted leukemogenesis with a significantly shortened latency. Pbrm1-deficient leukemia cells were less immunogenic and were characterized by attenuated interferon signaling and reduced major histocompatibility complex class II (MHC II) expression. We explored the potential relevance to human leukemia by assessing the involvement of PBRM1 in the control of interferon pathway components and found that PBRM1 binds to the promoters of a subset of these genes, most notably IRF1, which in turn regulates MHC II expression. Our findings revealed a novel role for Pbrm1 in leukemia progression. More generally, CRISPR/Cas9 screening coupled with phenotypic readouts in vivo has helped identify a pathway by which transcriptional control of interferon signaling influences leukemia cell interactions with the immune system.
引用
- Li BE, Li GY, Cai W, et al. In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice. Blood Adv. 2023. PMID: 37428871. doi:10.1182/bloodadvances.2022009455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。